Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Characterization of circulating RSV strains among subjects in the OUTSMART-RSV surveillance program during the 2016-17 winter viral season in the United States.

Ruzin A, Pastula ST, Levin-Sparenberg E, Jiang X, Fryzek J, Tovchigrechko A, Lu B, Qi Y, Liu H, Jin H, Yu L, Hackett J, Villafana T, Esser MT.

PLoS One. 2018 Jul 24;13(7):e0200319. doi: 10.1371/journal.pone.0200319. eCollection 2018.

2.

Generalized ROC methods for immunogenicity data analysis of vaccine phase I studies in a seropositive population.

Yu L, Esser MT, Falloon J, Villafana T, Yang H.

Hum Vaccin Immunother. 2018;14(11):2692-2700. doi: 10.1080/21645515.2018.1489191. Epub 2018 Jul 12.

3.

Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants.

Domachowske JB, Khan AA, Esser MT, Jensen K, Takas T, Villafana T, Dubovsky F, Griffin MP.

Pediatr Infect Dis J. 2018 Sep;37(9):886-892. doi: 10.1097/INF.0000000000001916.

4.

An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults.

Falloon J, Yu J, Esser MT, Villafana T, Yu L, Dubovsky F, Takas T, Levin MJ, Falsey AR.

J Infect Dis. 2017 Dec 12;216(11):1362-1370. doi: 10.1093/infdis/jix503.

5.

Vaccine development and trials in low and lower-middle income countries: Key issues, advances and future opportunities.

Grenham A, Villafana T.

Hum Vaccin Immunother. 2017 Sep 2;13(9):2192-2199. doi: 10.1080/21645515.2017.1356495. Review.

6.

Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses.

Falloon J, Talbot HK, Curtis C, Ervin J, Krieger D, Dubovsky F, Takas T, Yu J, Yu L, Lambert SL, Villafana T, Esser MT.

Clin Vaccine Immunol. 2017 Sep 5;24(9). pii: e00157-17. doi: 10.1128/CVI.00157-17. Print 2017 Sep.

7.

Passive and active immunization against respiratory syncytial virus for the young and old.

Villafana T, Falloon J, Griffin MP, Zhu Q, Esser MT.

Expert Rev Vaccines. 2017 Jul;16(7):1-13. doi: 10.1080/14760584.2017.1333425. Epub 2017 Jun 7. Review.

PMID:
28525961
8.

Hospitalizations for Respiratory Syncytial Virus Among Adults in the United States, 1997-2012.

Pastula ST, Hackett J, Coalson J, Jiang X, Villafana T, Ambrose C, Fryzek J.

Open Forum Infect Dis. 2017 Jan 9;4(1):ofw270. doi: 10.1093/ofid/ofw270. eCollection 2017 Winter.

9.

Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults.

Griffin MP, Khan AA, Esser MT, Jensen K, Takas T, Kankam MK, Villafana T, Dubovsky F.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e01714-16. doi: 10.1128/AAC.01714-16. Print 2017 Mar.

10.

A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant.

Falloon J, Ji F, Curtis C, Bart S, Sheldon E, Krieger D, Dubovsky F, Lambert S, Takas T, Villafana T, Esser MT.

Vaccine. 2016 May 27;34(25):2847-54. doi: 10.1016/j.vaccine.2016.04.002. Epub 2016 Apr 19.

11.

Recruitment and retention of pregnant women into clinical research trials: an overview of challenges, facilitators, and best practices.

Frew PM, Saint-Victor DS, Isaacs MB, Kim S, Swamy GK, Sheffield JS, Edwards KM, Villafana T, Kamagate O, Ault K.

Clin Infect Dis. 2014 Dec 15;59 Suppl 7:S400-7. doi: 10.1093/cid/ciu726.

12.

Femtosecond pump-probe microscopy generates virtual cross-sections in historic artwork.

Villafana TE, Brown WP, Delaney JK, Palmer M, Warren WS, Fischer MC.

Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):1708-13. doi: 10.1073/pnas.1317230111. Epub 2014 Jan 21.

13.

Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02(D) malaria vaccine in infants living in a malaria-endemic region.

Abdulla S, Salim N, Machera F, Kamata R, Juma O, Shomari M, Kubhoja S, Mohammed A, Mwangoka G, Aebi T, Mshinda H, Schellenberg D, Carter T, Villafana T, Dubois MC, Leach A, Lievens M, Vekemans J, Cohen J, Ballou WR, Tanner M.

Malar J. 2013 Jan 8;12:11. doi: 10.1186/1475-2875-12-11.

14.

Pump-probe imaging of historical pigments used in paintings.

Samineni P, deCruz A, Villafaña TE, Warren WS, Fischer MC.

Opt Lett. 2012 Apr 15;37(8):1310-2. doi: 10.1364/OL.37.001310.

PMID:
22513669
15.

Antigen-specific IL-2 secretion correlates with NK cell responses after immunization of Tanzanian children with the RTS,S/AS01 malaria vaccine.

Horowitz A, Hafalla JC, King E, Lusingu J, Dekker D, Leach A, Moris P, Cohen J, Vekemans J, Villafana T, Corran PH, Bejon P, Drakeley CJ, von Seidlein L, Riley EM.

J Immunol. 2012 May 15;188(10):5054-62. doi: 10.4049/jimmunol.1102710. Epub 2012 Apr 13.

16.

Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria.

Olotu A, Moris P, Mwacharo J, Vekemans J, Kimani D, Janssens M, Kai O, Jongert E, Lievens M, Leach A, Villafana T, Savarese B, Marsh K, Cohen J, Bejon P.

PLoS One. 2011;6(10):e25786. doi: 10.1371/journal.pone.0025786. Epub 2011 Oct 6.

17.

Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine.

Swysen C, Vekemans J, Bruls M, Oyakhirome S, Drakeley C, Kremsner P, Greenwood B, Ofori-Anyinam O, Okech B, Villafana T, Carter T, Savarese B, Duse A, Reijman A, Ingram C, Frean J, Ogutu B; Clinical Trials Partnership Committee.

Malar J. 2011 Aug 4;10:223. doi: 10.1186/1475-2875-10-223.

18.

Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children.

Bejon P, Cook J, Bergmann-Leitner E, Olotu A, Lusingu J, Mwacharo J, Vekemans J, Njuguna P, Leach A, Lievens M, Dutta S, von Seidlein L, Savarese B, Villafana T, Lemnge MM, Cohen J, Marsh K, Corran PH, Angov E, Riley EM, Drakeley CJ.

J Infect Dis. 2011 Jul 1;204(1):9-18. doi: 10.1093/infdis/jir222.

19.

Induction of Plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D).

Agnandji ST, Fendel R, Mestré M, Janssens M, Vekemans J, Held J, Gnansounou F, Haertle S, von Glasenapp I, Oyakhirome S, Mewono L, Moris P, Lievens M, Demoitie MA, Dubois PM, Villafana T, Jongert E, Olivier A, Cohen J, Esen M, Kremsner PG, Lell B, Mordmüller B.

PLoS One. 2011 Apr 11;6(4):e18559. doi: 10.1371/journal.pone.0018559.

20.

Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial.

Olotu A, Lusingu J, Leach A, Lievens M, Vekemans J, Msham S, Lang T, Gould J, Dubois MC, Jongert E, Vansadia P, Carter T, Njuguna P, Awuondo KO, Malabeja A, Abdul O, Gesase S, Mturi N, Drakeley CJ, Savarese B, Villafana T, Lapierre D, Ballou WR, Cohen J, Lemnge MM, Peshu N, Marsh K, Riley EM, von Seidlein L, Bejon P.

Lancet Infect Dis. 2011 Feb;11(2):102-9. doi: 10.1016/S1473-3099(10)70262-0. Epub 2011 Jan 13. Erratum in: Lancet Infect Dis. 2011 Mar;11(3):159.

21.

Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children.

Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, Olivier A, Benns S, Olomi R, Msham S, Lang T, Gould J, Hallez K, Guerra Y, Njuguna P, Awuondo KO, Malabeja A, Abdul O, Gesase S, Dekker D, Malle L, Ismael S, Mturi N, Drakeley CJ, Savarese B, Villafana T, Ballou WR, Cohen J, Riley EM, Lemnge MM, Marsh K, Bejon P, von Seidlein L.

PLoS One. 2010 Nov 29;5(11):e14090. doi: 10.1371/journal.pone.0014090. Erratum in: PLoS One. 2010; 5(12) doi: 10.1371/annotation/3b62fdef-4cdd-40cc-b69d-69afd2000c4f. PLoS One. 2010;5(12) doi: 10.1371/annotation/0543a689-83a6-4528-92a1-a0f978b47fcb.

22.

Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization.

Agnandji ST, Asante KP, Lyimo J, Vekemans J, Soulanoudjingar SS, Owusu R, Shomari M, Leach A, Fernandes J, Dosoo D, Chikawe M, Issifou S, Osei-Kwakye K, Lievens M, Paricek M, Apanga S, Mwangoka G, Okissi B, Kwara E, Minja R, Lange J, Boahen O, Kayan K, Adjei G, Chandramohan D, Jongert E, Demoitié MA, Dubois MC, Carter T, Vansadia P, Villafana T, Sillman M, Savarese B, Lapierre D, Ballou WR, Greenwood B, Tanner M, Cohen J, Kremsner PG, Lell B, Owusu-Agyei S, Abdulla S.

J Infect Dis. 2010 Oct 1;202(7):1076-87. doi: 10.1086/656190. Erratum in: J Infect Dis. 2011 May 1;203(9):1344.

PMID:
20735271
23.

A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon.

Lell B, Agnandji S, von Glasenapp I, Haertle S, Oyakhiromen S, Issifou S, Vekemans J, Leach A, Lievens M, Dubois MC, Demoitie MA, Carter T, Villafana T, Ballou WR, Cohen J, Kremsner PG.

PLoS One. 2009 Oct 27;4(10):e7611. doi: 10.1371/journal.pone.0007611.

24.

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age.

Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, Mshamu S, Lang T, Gould J, Dubois MC, Demoitié MA, Stallaert JF, Vansadia P, Carter T, Njuguna P, Awuondo KO, Malabeja A, Abdul O, Gesase S, Mturi N, Drakeley CJ, Savarese B, Villafana T, Ballou WR, Cohen J, Riley EM, Lemnge MM, Marsh K, von Seidlein L.

N Engl J Med. 2008 Dec 11;359(24):2521-32. doi: 10.1056/NEJMoa0807381. Epub 2008 Dec 8.

25.

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants.

Abdulla S, Oberholzer R, Juma O, Kubhoja S, Machera F, Membi C, Omari S, Urassa A, Mshinda H, Jumanne A, Salim N, Shomari M, Aebi T, Schellenberg DM, Carter T, Villafana T, Demoitié MA, Dubois MC, Leach A, Lievens M, Vekemans J, Cohen J, Ballou WR, Tanner M.

N Engl J Med. 2008 Dec 11;359(24):2533-44. doi: 10.1056/NEJMoa0807773. Epub 2008 Dec 8.

26.

Basic science curriculums in nuclear cardiology and cardiovascular imaging: evolving and emerging concepts.

Van Decker WA, Villafana T.

J Nucl Cardiol. 2008 Jul-Aug;15(4):587-94. doi: 10.1016/j.nuclcard.2008.05.008. Review.

PMID:
18674726
27.

The HVTN protocol 903 vaccine preparedness study: lessons learned in preparation for HIV vaccine efficacy trials.

Djomand G, Metch B, Zorrilla CD, Donastorg Y, Casapia M, Villafana T, Pape J, Figueroa P, Hansen M, Buchbinder S, Beyrer C; 903 Protocol Team.

J Acquir Immune Defic Syndr. 2008 May 1;48(1):82-9. doi: 10.1097/QAI.0b013e31817236ab.

PMID:
18391750
28.

Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults.

Gorse GJ, Baden LR, Wecker M, Newman MJ, Ferrari G, Weinhold KJ, Livingston BD, Villafana TL, Li H, Noonan E, Russell ND; HIV Vaccine Trials Network.

Vaccine. 2008 Jan 10;26(2):215-23. Epub 2007 Nov 20.

PMID:
18055072
29.

CT and MR evaluation of a wooden foreign body in an in vitro model of the orbit.

McGuckin JF Jr, Akhtar N, Ho VT, Smergel EM, Kubacki EJ, Villafana T.

AJNR Am J Neuroradiol. 1996 Jan;17(1):129-33.

30.

Technologic advances in computed tomography.

Villafana T.

Curr Opin Radiol. 1991 Apr;3(2):275-83.

PMID:
2049277
31.

Generators, x-ray tubes, and exposure geometry in mammography.

Villafana T.

Radiographics. 1990 May;10(3):539-54.

PMID:
2343172
32.

Quality assurance breast phantoms for screen-film mammography: design and use.

Stanton L, Villafana T.

Appl Radiol. 1989 Nov;18(11):41-8.

PMID:
10304413
33.

Fundamental physics of magnetic resonance imaging.

Villafana T.

Radiol Clin North Am. 1988 Jul;26(4):701-15. Erratum in: Radiol Clin North Am 1989 Jan;27(1):xi.

PMID:
3380941
34.

Screen-film mammographic technique for breast cancer screening.

Stanton L, Day JL, Villafana T, Miller CH, Lightfoot DA.

Radiology. 1987 May;163(2):471-9.

PMID:
3562829
35.

The retrolenticular afterglow: an echo enhancement artifact.

Ziskin MC, LaFollette PS Jr, Radecki PD, Villafana T.

J Ultrasound Med. 1986 Jul;5(7):385-9.

PMID:
3522929
36.

Dosage evaluation in mammography.

Stanton L, Villafana T, Day JL, Lightfoot DA.

Radiology. 1984 Feb;150(2):577-84.

PMID:
6691119
37.

Improved technique for dose reduction and organ localization in intravenous urography.

Mayer DP, Villafana T, Shea FJ, Shields D, Lapayowker MS.

Radiology. 1982 Jul;144(1):177-8. No abstract available.

PMID:
7089254
38.

Measurements of diagnostic x-ray backscatter by a novel ion chamber method.

Stanton L, Brattelli SD, Day JL, Stanton RE, Villafana T.

Med Phys. 1982 Jan-Feb;9(1):121-30.

PMID:
7078527
39.

Interpretation of measured exposure rate levels in diagnostic radiology.

Villafana T.

Health Phys. 1981 Mar;40(3):394-9. No abstract available.

PMID:
7228690
40.

Localization of vertex lesions on cranial computed tomography.

Lee SH, Villafana T.

Radiology. 1980 Feb;134(2):539-40. No abstract available.

PMID:
7352248
41.

Device for correlating CT and radiation therapy portal images.

Villafana T, Lee SH, Vider M, Wu RK.

AJR Am J Roentgenol. 1979 Dec;133(6):1191-3. No abstract available.

PMID:
116519
42.

A study of mammographic exposure and detail visibility using three systems: Xerox 125, Min-R, and Xonics XERG.

Stanton L, Villafana T, Day JL, Lightfoot DA, Stanton RE.

Radiology. 1979 Aug;132(2):455-62.

PMID:
461808
43.

Rapid computation of diagnostic X-ray bremsstrahlung spectra.

Stanton L, Day JL, Lightfoot DA, Villafana T, Rauch PL.

Radiology. 1979 Feb;130(2):477-84.

PMID:
760166
44.

A breast phantom method for evaluating mammography technique.

Stanton L, Villafana T, Day JL, Lightfoot DA.

Invest Radiol. 1978 Jul-Aug;13(4):291-7.

PMID:
689822
45.

A device to indicate anatomical level in computed tomography.

Villafana T, Lee SH, Lapayowker MS.

J Comput Assist Tomogr. 1978 Jul;2(3):368-71.

PMID:
263502
46.

CT intracranial localization with a new marker system.

Lee SH, Villafana T, Lapayowker MS.

Neuroradiology. 1978;16:570-1.

PMID:
745760
47.

Temporal response of microdensitometers.

Villafana T.

Med Phys. 1978 Jan-Feb;5(1):34-6.

PMID:
634232
48.

Health physics aspects of the EMI computerized tomography brain scanner.

Villafana T, Scouras J, Kirkland L, McElroy N, Paras P.

Health Phys. 1978 Jan;34(1):71-82. No abstract available.

PMID:
621156
49.
50.

Effect of microdensitometer scan slit misalignment in MTF determinations.

Villafana T.

Med Phys. 1975 Sep-Oct;2(5):255-8.

PMID:
1186631

Supplemental Content

Loading ...
Support Center